Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial Evaluating the Safety and Efficacy of Point-of-care CAR-T-cell Therapy in the Treatment of Relapsed/Refractory CD19+ Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

NCT06027957 is registered in ClinicalTrials.gov with Vinmec Research Institute of Stem Cell and Gene Technology as lead sponsor.

NCT NCT06027957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06027957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial Evaluating the Safety and Efficacy of Point-of-care CAR-T-cell Therapy in the Treatment of Relapsed/Refractory CD19+ Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Lead sponsor
Vinmec Research Institute of Stem Cell and Gene Technology
Phase
Phase 1
Overall status
Completed
Start date
August 2, 2023
Completion date
July 31, 2025
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, b-cell non hodgkin lymphoma